Equities

Organogenesis Holdings Inc

Organogenesis Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.75
  • Today's Change0.02 / 0.73%
  • Shares traded1.04m
  • 1 Year change-24.24%
  • Beta1.6588
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

  • Revenue in USD (TTM)435.47m
  • Net income in USD5.82m
  • Incorporated2018
  • Employees862.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nautilus Biotechnology Inc0.00-67.44m343.23m163.00--1.38-----0.5402-0.54020.001.990.00----0.00-21.26---21.85--------------0.00-------9.93------
Anavex Life Sciences Corp0.00-40.59m343.64m40.00--2.52-----0.4962-0.49620.001.610.00----0.00-26.73-40.04-28.98-43.97------------0.00------0.9857------
C4 Therapeutics Inc20.04m-126.07m344.03m145.00--1.33--17.17-2.37-2.370.36773.760.0504--2.84138,179.30-31.74-25.91-36.02-29.45-----629.24-292.35----0.00---33.251.40-3.37---8.68--
Sutro Biopharma Inc154.07m-114.96m345.58m300.00--2.69--2.24-1.89-1.892.531.570.4047--7.48510,149.00-30.20-25.48-36.94-29.75-----74.62-113.71----0.00--126.8431.9610.41--22.61--
OraSure Technologies, Inc.304.64m22.85m349.83m638.0015.560.82078.171.150.3040.3044.115.760.65732.774.31477,493.704.930.72385.420.821245.2646.947.501.1310.49--0.00170.004.6417.41413.1782.2010.18--
Shattuck Labs Inc2.72m-85.08m350.93m75.00--2.72--129.25-1.93-1.930.06082.710.0168----36,200.00-52.52-29.14-57.94-32.42-----3,133.63-565.33----0.00--154.14-40.6214.37---19.15--
Tourmaline Bio Inc0.00-32.94m353.15m44.00--0.9972-----5.35-5.350.0013.810.00----0.00-12.39---12.75--------------0.00------42.99------
Precigen Inc5.44m-96.91m353.39m202.00--3.61--64.97-0.3896-0.38960.02190.38770.0289--4.1226,925.74-51.49-31.50-64.42-38.63-4.1944.00-1,781.73-232.32----0.00---76.87-47.16-20.22---48.30--
Amarin Corporation plc (ADR)277.46m-52.61m355.40m275.00--0.6508--1.28-0.1288-0.12880.6791.330.33630.41972.231,008,927.00-6.38-4.48-8.90-6.5463.6175.70-18.96-8.591.93--0.00---16.876.0144.13--55.83--
Cibus Inc2.32m-285.67m356.99m183.00--1.09--153.87-18.29-18.290.152213.240.0084----12,677.60-129.84-86.28-147.90-96.45-----15,483.49-792.07---3.170.0039--1,057.3350.41-1,484.44--18.53--
Verrica Pharmaceuticals Inc8.91m-80.74m360.99m100.00--239.39--40.50-1.75-1.750.19290.03560.1321--2.3389,130.00-119.66-55.75-142.98-78.3379.63---905.83-754.943.04-21.710.9678---43.27---173.59--5.65--
Aura Biosciences Inc0.00-78.65m364.14m88.00--1.74-----1.86-1.860.004.220.00----0.00-35.66---37.16--------------0.00-------30.03------
Organogenesis Holdings Inc435.47m5.82m364.57m862.0063.251.3117.170.83720.04350.04353.282.110.96284.084.63505,190.301.295.461.566.9075.0774.941.344.812.418.780.19550.00-3.9417.49-68.16--67.34--
Biomea Fusion Inc0.00-127.27m378.14m110.00--2.79-----3.57-3.570.003.770.00----0.00-90.54---107.35--------------0.00-------43.29------
Anika Therapeutics Inc169.26m-76.83m380.35m357.00--1.82--2.25-5.24-5.2411.5414.070.56161.425.40474,120.40-25.49-5.41-28.16-5.8761.9660.70-45.39-12.603.85--0.00--6.679.56-456.34--3.11--
enGene Holdings Inc0.00-106.80m387.65m33.00--3.27-----4.60-4.600.002.69------0.00-------------------1.370.2653-------260.87------
Data as of May 31 2024. Currency figures normalised to Organogenesis Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

30.78%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. LLCas of 31 Mar 202411.45m8.67%
Soleus Capital Management LP (Investment Management)as of 31 Mar 20249.57m7.25%
BlackRock Fund Advisorsas of 31 Mar 20244.44m3.37%
The Vanguard Group, Inc.as of 31 Mar 20243.46m2.62%
Acadian Asset Management LLCas of 31 Mar 20243.00m2.28%
DWS Investments (UK) Ltd.as of 31 Mar 20242.51m1.90%
Geode Capital Management LLCas of 31 Mar 20241.75m1.33%
Dimensional Fund Advisors LPas of 31 Mar 20241.70m1.29%
SSgA Funds Management, Inc.as of 31 Mar 20241.45m1.10%
AQR Capital Management LLCas of 31 Mar 20241.28m0.97%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.